← Leaderboards
Angus Hucknall
Gateway Bio, Inc.
$1,388,111
Attributed
$2,184,577
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,184,577 · 4
By mechanism
R44$1,278,585 · 1
R41$905,992 · 3
Top collaborators
- Ashutosh Chilkoti3 shared
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesStructurePolyethylene GlycolsVertebral ColumnGlycolsPolymersEthylene GlycolImmunogenicityExhibitsTechnologyPropertyFormulationCirculationBiological ProductsDrug KineticsAllergic ReactionArchitectureEffectivenessPharmaceutical PreparationsSuccessHigh Pressure Liquid ChromatographyHalf-LifeHourFda Approved
Grant awards (5)
Scale-up and Toxicity Studies of POEGMA-Uricase$639,413
R44 · FY2025 · TR · contact PI
Next Generation Stealth Lipid for the Delivery of mRNA$314,347
R41 · FY2025 · AI · contact PI
Novel Stealth Lipid for use in HIV MPER Vaccine$303,173
R41 · FY2025 · AI · contact PI
Scale-up and Toxicity Studies of POEGMA-Uricase$639,172
R44 · FY2024 · TR · contact PI
Non-Immunogenic PEG-like Conjugates of Uricase$288,472
R41 · FY2020 · TR · contact PI